Ausper Bio successfully raised $63 million in a Series B2 financing round to accelerate the development of its innovative hepatitis B treatment, AHB-137.
Target Information
Ausper Biopharma Co., Ltd. and AusperBio Therapeutics Inc., collectively known as AusperBio, is a clinical-stage innovative pharmaceutical company focused on achieving clinical cure for chronic hepatitis B through the research and development of innovative targeted delivery small nucleic acid drugs. The company has announced the successful completion of a $63 million Series B2 financing round.
This financing round was co-led by Qiming Venture Partners and marks AusperBio's second round of financing in 2025, bringing the total funds raised by the company this year to over $113 million. The funds raised will primarily serve to accelerate the development of AusperBio’s core product, AHB-137, an antisense oligonucleotide (ASO) innovative drug aimed at achieving clinical cure for chronic hepatitis B.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The biopharmaceutical industry in China is rapidly evolving, with significant investments being made in research and development. This sector has been bolstered by favorable government policies aimed at fostering innovation an
Similar Deals
启明创投
invested in
浩博医药
in 2025
in a Series B deal
Disclosed details
Transaction Size: $63M